Point Of Care Infectious Disease Testing Market Summary

The global point of care infectious disease testing market size was valued at USD 11.40 billion in 2023 and is projected to reach USD 15.76 billion by 2030, growing at a CAGR of 4.3% from 2024 to 2030. This growth is largely driven by the rising incidence of infectious diseases, the increasing need for precise and rapid diagnostic tools, and continuous technological advancements such as molecular diagnostics and agglutination tests. These innovations are enabling faster detection, higher accuracy, and more efficient disease management across both developed and developing healthcare settings.

The rising prevalence of contagious diseases, coupled with an expanding aging population that requires timely medical attention, is significantly contributing to the market expansion. Supportive government policies encouraging the adoption of point of care (POC) testing are further strengthening the market outlook. Moreover, the growing demand for diagnostic tools is fueled by the increasing number of infectious diseases such as HIV, hepatitis, and tuberculosis. With many illnesses requiring early detection for effective treatment, point-of-care tests are becoming increasingly common in hospitals, clinics, and remote healthcare facilities.

Key Market Trends & Insights

• The North America point of care infectious disease testing market dominated the global market with a revenue share of 51.0% in 2023, supported by advanced healthcare infrastructure and high adoption of innovative diagnostic technologies.
• The U.S. point of care infectious disease diagnostics segment dominated the North America market with a share of 82.6% in 2023, owing to strong investments in research, extensive testing initiatives, and widespread availability of rapid diagnostic solutions.
• The Asia Pacific point of care infectious disease diagnostics market is anticipated to witness the fastest CAGR of 5.0% during the forecast period, driven by expanding healthcare access, rising awareness of early disease detection, and increasing government focus on infectious disease control.
• Based on technology, molecular diagnostics accounted for the largest market revenue share of 43.0% in 2023, reflecting the growing preference for highly accurate and sensitive testing methods.
• In terms of disease, the COVID-19 segment dominated the market and accounted for a share of 67% in 2023, highlighting the continued need for rapid testing solutions during and after the pandemic.

Order a free sample PDF of the Point Of Care Infectious Disease Testing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 11.40 Billion
• 2030 Projected Market Size: USD 15.76 Billion
• CAGR (2024-2030): 4.3%
• North America: Largest market in 2023
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

Some of the key companies in the point of care infectious disease testing market include Abbott; Thermo Fisher Scientific Inc; F. Hoffmann-La Roche Ltd; Siemens Healthineers; Quest Diagnostics Incorporated. Organizations are focusing on increasing customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies.

Key Players

• Abbott
• Thermo Fisher Scientific Inc
• Hoffmann-La Roche Ltd
• Siemens Healthineers
• Becton, Dickinson & Company
• Chembio Diagnostics Inc.
• Trinity Biotech
• Cardinal Health
• Quest Diagnostics Incorporated
• Bio-Rad Laboratories Inc.
• bioMérieux SA
• Sight Diagnostics Ltd.
• Gene POC
• Trivitron Healthcare
• OJ-Bio Ltd.
• Ortho-Clinical Diagnostics.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

Overall, the point of care infectious disease testing market is poised for sustained growth as the need for quick, reliable, and accessible diagnostic solutions continues to expand worldwide. With infectious diseases remaining a major public health concern, rapid tests play a vital role in early detection, efficient treatment, and effective disease management. Technological advancements, supportive government initiatives, and growing healthcare awareness are collectively strengthening market adoption. While North America maintains a leading position, emerging markets in Asia Pacific are gaining momentum. As healthcare systems increasingly prioritize timely diagnosis, the relevance of point-of-care testing is expected to grow substantially in the coming years.